Opioids and risk of type 2 diabetes in adults with non-cancer pain

Pain Physician

Volumn 16, Issue 1, 2013, Pages 77-88

  Li, Lin ^a   Setoguchi, Soko ^b   Cabral, Howard ^c   Jick, Susan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adults; General practice research database gprd; Nested case control; Non cancer pain; Opioids; Safety; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DIHYDROCODEINE; FENTANYL; MEPTAZINOL; MORPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PARACETAMOL; PETHIDINE; STEROID; TRAMADOL;

ADULT; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON-CANCER PAIN; PAIN; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

EID: 84872765848     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage 2003; 26:1026-1048.
2. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
3. Gallagher RM, Rosenthal LJ. Chronic pain and opiates: Balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 2008; 89:S77-S82.
4. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8:287-313.
5. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008; 11:S181-S200.
6. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008; 11:S5-S62.
7. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic nonmalignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7:R1046-R1051.
8. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008; 11:S105-S120.
9. U.S. Food and Drug Administration, MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Propoxyphene: Withdrawal-risk of cardiac toxicity. Available at: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm234389.htm; accessed 05/10/2011.
10. Azizi F, Vagenakis AG, Longcope C, Ingbar SH, Braverman LE. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids 1973; 22:467-472.
11. Cushman P, Jr. Plasma testosterone in narcotic addiction. Am J Med 1973; 55:452-458.
12. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 1975; 192:211-217.
13. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85:2215-2222.
14. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3:377-384.
15. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000; 16:251-254.
16. Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex hormone suppression by intrathecal opioids: A prospective study. Clin J Pain 2002; 18:144-148.
17. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain 2006; 7:901-907.
18. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008; 9:28-36.
19. Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Nicholson LR, Bureau Y, Friedman TC, Van Uum SH. Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 2009; 117:38-43.
20. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24:183-217.
21. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30:911-917.
22. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006; 295:1288-1299.
23. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:5462-5468.
24. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002; 25:55-60.
25. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23:490-494.
26. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormonebinding globulin and testosterone predict the development of non-insulindependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143:889-897.
27. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E; Heart and Estrogen/ Progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:1-9.
28. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV; Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47:1175-1187.
29. Colameco S, Coren JS. Opioid-induced endocrinopathy. J Am Osteopath Assoc 2009; 109:20-25.
30. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009;25:170-175.
31. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302:766-768.
32. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1:347-349.
33. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 2003; 23:686-689.
34. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 2010; 69:4-14.
35. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2007; 16:979-987.
36. Shawe J, Mulnier H, Nicholls P, Lawrenson R. Use of hormonal contraceptive methods by women with diabetes. Prim Care Diabetes 2008; 2:195-199.
37. MedlinePlus, U.S. National Library of Medicine, National Institutes of Health. Type 2 diabetes - risk factors. Available at: www.nlm.nih.gov/medlineplus/ency/article/002072.htm; accessed 06/30/2011.
38. Clore JN, Thurby-Hay L. Glucocorticoidinduced hyperglycemia. Endocr Pract 2009; 15:469-474.
39. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
40. Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010; 33:1618-1624.
41. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000; 23:912-918.
42. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63:239-250.
43. Godsland IF. Oestrogens and insulin secretion. Diabetologia 2005; 48:2213-2220.
44. Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, Cole SR, Cohen MH, Kovacs A, Augenbraun M, Latham PS, Tien PC. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010; 54:152-159.
45. Bradbury RA, Samaras K. Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost? Diabetes Obes Metab 2008; 10:441-450.
46. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. Clin J Pain 2008; 24:497-508.
47. Newnham A, Ryan R, Khunti K, Majeed A. Prevalence of diagnosed diabetes mellitus in general practice in England and Wales, 1994 to 1998. Health Statistics Quarterly 2002; 14:5-13.